> Details

Galbiati, Silvia; Causarano, Vincenza; Pinzani, Pamela; Francesca, Salvianti; Orlando, Claudio; Smid, Maddalena; Pasi, Federica; Castiglioni, Maria T.; Cavoretto, Paolo; Rovere-Querini, Patrizia; Pedroni, Silvia; Calza, Stefano; Ferrari, Maurizio; Cremonesi, Laura

Evaluation of a panel of circulating DNA, RNA and protein potential markers for pathologies of pregnancy

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Evaluation of a panel of circulating DNA, RNA and protein potential markers for pathologies of pregnancy
  • Contributor: Galbiati, Silvia; Causarano, Vincenza; Pinzani, Pamela; Francesca, Salvianti; Orlando, Claudio; Smid, Maddalena; Pasi, Federica; Castiglioni, Maria T.; Cavoretto, Paolo; Rovere-Querini, Patrizia; Pedroni, Silvia; Calza, Stefano; Ferrari, Maurizio; Cremonesi, Laura
  • imprint: Walter de Gruyter GmbH, 2010
  • Published in: cclm
  • Language: English
  • DOI: 10.1515/cclm.2010.160
  • ISSN: 1437-4331; 1434-6621
  • Origination:
  • Footnote:
  • Description: <jats:title>Abstract</jats:title> <jats:p> <jats:bold>Background:</jats:bold> Among markers of pregnancy complications, corticotropin-releasing hormone (<jats:italic>CRH</jats:italic>) mRNA, long pentraxin 3 (PTX3) protein and fetal and total DNA had been reported to be increased in the plasma of women with overt preeclampsia (PE). We developed an optimized protocol to evaluate whether concentrations of <jats:italic>CRH</jats:italic> mRNA, <jats:italic>PTX3</jats:italic> mRNA and protein, fetal and/or total DNA are increased in fetal growth restriction (FGR), and whether they predict complications of pregnancy.</jats:p> <jats:p> <jats:bold>Methods:</jats:bold> The protocol included a preamplification step to enrich rare mRNA species. <jats:italic>CRH</jats:italic> and <jats:italic>PTX3</jats:italic> mRNA, DNA and PTX3 protein were measured in the plasma of women with PE or FGR, in women at risk of developing these pathologies and in healthy women matched for gestational age.</jats:p> <jats:p> <jats:bold>Results:</jats:bold> <jats:italic>CRH</jats:italic> mRNA, fetal and/or total DNA and PTX3 protein were significantly increased in women with overt PE when compared to controls. Pregnant women who later developed PE or FGR during pregnancy showed total DNA levels that were significantly increased before the onset of both pathologies, while RNA markers were increased only in women who later developed PE.</jats:p> <jats:p> <jats:bold>Conclusions:</jats:bold> Our protocol for plasma RNA quantification may allow for the extension of a panel of predictive markers to be investigated in larger patient cohorts.</jats:p> <jats:p>Clin Chem Lab Med 2010;48:791–4.</jats:p>